Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Recent clinical trials have shown that dual and triple agonists targeting these pathways can lead to superior reductions in body weight and liver fat compared to GLP-1R mono-agonists, with a comparable safety profile [16,17,18,19,20,21,22]
She then led Kaiser Addiction Medicine programs in the Bay Area and served as the Clinical Director of Psychiatry at the Kaiser South Sacramento Medical Center, where she oversaw comprehensive behavioral health services, including Adult and Child Psychiatry, Addiction Medicine, and Intensive Outpatient Services
Exenatide use was associated with a 72% reduction (OR = 0.28, 95% CI: 0.13-0.59, p = 0.0008), and liraglutide with a 71% reduction (OR = 0.29, 95% CI: 0.19-0.46, p = 0.0001)
GLP-1 drugs are effective: There is a substantial body of scientific research supporting the effectiveness of these medications for several weight-related health concerns
